Physician profile

Ilya Zavelsky

Pediatrics · King George, VA

NPI 1336386309

$261.74

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$98.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Cranial Technologies, INC $50.03 2019-2021
Takeda Pharmaceuticals U.S.A., INC. $39.28 2019-2020
Merck Sharp & Dohme LLC $30.88 2023-2024 Proquad, Vaxneuvance, Gardasil 9
Corium, LLC $30.41 2023 Azstarys
Sanofi Pasteur INC. $29.06 2021-2023
Ironshore Pharmaceuticals INC. $27.54 2019
Supernus Pharmaceuticals, INC. $22.99 2023 Qelbree
Adlon Therapeutics L.P. $19.41 2020
Tris Pharma INC $12.14 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ilya Zavelsky

$261.74

in general payments reported 2019-2025

Years
2019-2024
Top company
Cranial Technologies, INC

https://glasscript.com/doctor/970982/ilya-zavelsky

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.